The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smyth, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smyth, M. J.

The Journal of Immunology, Vol 158, Issue 12 5765-5772, Copyright © 1997 by American Association of Immunologists


ARTICLES

Fas ligand-mediated bystander lysis of syngeneic cells in response to an allogeneic stimulus

MJ Smyth
Cellular Cytotoxicity Laboratory, The Austin Research Institute, Heidelberg, Victoria, Australia. mj_smyth@muwayf.unimelb.edu.au

Using a mouse allospecific lymph node (LN) CTL (H-2b) response to transplanted cells (H-2k), effector cells were shown to lyse C3H/HeJ or L929-Fas (H-2k) target cells in either a perforin-dependent or a Fas ligand (FasL)-dependent manner. C3H/HeJ.lpr targets or L929 targets lacking Fas were not sensitive to these effectors generated in perforin- deficient (Po) mice. By contrast, C3H/HeJ.lpr target cells and L929 were as responsive as C3H/HeJ and L929-Fas targets to the effectors generated in perforin wild-type (P+/+) mice. To measure potential bystander lysis in allogeneic responses, these same effector LN from either C57BL/6 P+/+ or P(o) mice were examined for lysis of C3H/HeJ (or C3H/HeJ.lpr) or L929-Fas (or L929) cocultured with 51Cr-labeled C57BL/6 (H-2b) target cells. Bystander lysis of C57BL/6 targets was observed only in those allogeneic responses where FasL was the defined mechanism of lysis. By contrast, perforin-mediated lysis was restricted by allo- recognition. Syngeneic (H-2b) targets that were not sensitive to Fas- mediated lysis were not lysed in a bystander fashion. Depletion of subsets of LN Po effectors (b anti-k) demonstrated that CD4+ T cells were primarily responsible for FasL-mediated direct and bystander lysis. FasL-mediated bystander lysis was also observed in H-2k anti-b reactions, except when the effectors were FasL mutant (gld). These data suggest that CTL responses to foreign Ag may evoke a certain amount of collateral damage to local host Fas-sensitive cells.


This article has been cited by other articles:


Home page
J. Immunol.Home page
M.-T. Rubio, T. I. Saito, K. Kattleman, G. Zhao, J. Buchli, and M. Sykes
Mechanisms of the Antitumor Responses and Host-versus-Graft Reactions Induced by Recipient Leukocyte Infusions in Mixed Chimeras Prepared with Nonmyeloablative Conditioning: A Critical Role for Recipient CD4+ T Cells and Recipient Leukocyte Infusion-Derived IFN-{gamma}-Producing CD8+ T Cells
J. Immunol., July 15, 2005; 175(2): 665 - 676.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
M. Delgado, D. Pozo, and D. Ganea
The Significance of Vasoactive Intestinal Peptide in Immunomodulation
Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290.
[Abstract] [Full Text] [PDF]


Home page
Crit. Rev. Oral Biol. Med.Home page
D. Ganea and M. Delgado
VASOACTIVE INTESTINAL PEPTIDE (VIP) AND PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AS MODULATORS OF BOTH INNATE AND ADAPTIVE IMMUNITY
Crit. Rev. Oral. Biol. Med., May 1, 2002; 13(3): 229 - 237.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
E. J. Suchin, P. B. Langmuir, E. Palmer, M. H. Sayegh, A. D. Wells, and L. A. Turka
Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question
J. Immunol., January 15, 2001; 166(2): 973 - 981.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Delgado and D. Ganea
Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit T Cell-Mediated Cytotoxicity by Inhibiting Fas Ligand Expression
J. Immunol., July 1, 2000; 165(1): 114 - 123.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
S. J. Gagnon, F. A. Ennis, and A. L. Rothman
Bystander Target Cell Lysis and Cytokine Production by Dengue Virus-Specific Human CD4+ Cytotoxic T-Lymphocyte Clones
J. Virol., May 1, 1999; 73(5): 3623 - 3629.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
N. Kayagaki, N. Yamaguchi, M. Nakayama, A. Kawasaki, H. Akiba, K. Okumura, and H. Yagita
Involvement of TNF-Related Apoptosis-Inducing Ligand in Human CD4+ T Cell-Mediated Cytotoxicity
J. Immunol., March 1, 1999; 162(5): 2639 - 2647.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
A. A. ROSSINI, D. L. GREINER, and J. P. MORDES
Induction of Immunologic Tolerance for Transplantation
Physiol Rev, January 1, 1999; 79(1): 99 - 141.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J.-h. Li, D. Rosen, D. Ronen, C. K. Behrens, P. H. Krammer, W. R. Clark, and G. Berke
The Regulation of CD95 Ligand Expression and Function in CTL
J. Immunol., October 15, 1998; 161(8): 3943 - 3949.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. J. Sayers, A. D. Brooks, J.-K. Lee, R. G. Fenton, K. L. Komschlies, J. M. Wigginton, R. Winkler-Pickett, and R. H. Wiltrout
Molecular Mechanisms of Immune-Mediated Lysis of Murine Renal Cancer: Differential Contributions of Perforin-Dependent Versus Fas-Mediated Pathways in Lysis by NK and T Cells
J. Immunol., October 15, 1998; 161(8): 3957 - 3965.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. J. Smyth, E. Krasovskis, and R. W. Johnstone
Fas Ligand-Mediated Lysis of Self Bystander Targets by Human Papillomavirus-Specific CD8+ Cytotoxic T Lymphocytes
J. Virol., July 1, 1998; 72(7): 5948 - 5954.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. J. Smyth and J. A. Trapani
The Relative Role of Lymphocyte Granule Exocytosis versus Death Receptor-Mediated Cytotoxicity in Viral Pathophysiology
J. Virol., January 1, 1998; 72(1): 1 - 9.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.